AMG 757: all 30 studies that test it
Page 1 of 1. Open to participants first (20), then studies with results posted, then the rest; newest registration first within each.
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung CancerNot yet recruitingNCT07895056Phase 2
- Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusRecruitingNCT07803848Phase 2
- Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)Not yet recruitingNCT07788677Phase 1
- Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)RecruitingNCT07778316Phase 3
- Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung CancerNot yet recruitingNCT07637513Phase 3
- Tarlatamab for the Treatment of Extensive Stage Small-cell Lung CancerRecruitingNCT07423585Phase 2
- Tarlatamab for SCLC Brain MetastasesRecruitingNCT07402343Phase 2
- Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System TumorsRecruitingNCT07243470Phase 1/2
- Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC PatientsRecruitingNCT07242547Phase 2
- A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2RecruitingNCT07203053Phase 2
- A Study of Tarlatamab for People With Prostate CancerRecruitingNCT07111507Phase 2
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)RecruitingNCT07037758Phase 1
- Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)RecruitingNCT07016230Phase 2
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)RecruitingNCT06937905Phase 3
- Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma PatientsRecruitingNCT06893783Phase 2
- Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI TreatmentRecruitingNCT06830694Phase 2
- Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)RecruitingNCT06816394Phase 2
- Study of How Safe and Effective Tarlatamab is in Brain CancersRecruitingNCT06776250Phase 2
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)RecruitingNCT06598306Phase 1
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)RecruitingNCT06551142Phase 1
- Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentActive, not recruitingNCT06502977Phase 2Results posted
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerActive, not recruitingNCT05740566Phase 3Results posted
- AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)CompletedNCT04885998Phase 1Results posted
- A Study of AMG 757 in Participants With Neuroendocrine Prostate CancerCompletedNCT04702737Phase 1Results posted
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine CancerWithdrawnNCT07328490Phase 1/2
- A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT07005128Phase 3
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCActive, not recruitingNCT06745323Phase 2
- Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabActive, not recruitingNCT06211036Phase 3
- Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)Active, not recruitingNCT06117774Phase 3
- A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT05060016Phase 2